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STUDY PROTOCOL Open Access
Valaciclovir to prevent Cytomegalovirus
mediated adverse modulation of the
immune system in ANCA-associated
vasculitis (CANVAS): study protocol for a
randomised controlled trial
Dimitrios Chanouzas1, Lovesh Dyall1, Peter Nightingale2, Charles Ferro1, Paul Moss3, Matthew David Morgan1
and Lorraine Harper1*
Abstract
Background: The ANCA-associated vasculitides (AAV) are systemic autoimmune inflammatory disorders
characterised by necrotising inflammation affecting small to medium-sized blood vessels. Despite improvements in
survival, infection and cardiovascular disease remain leading causes of morbidity and mortality.
Considerable evidence suggests that CD4 + CD28null T-cell expansions, predominantly seen in Cytomegalovirus
(CMV) seropositive individuals, are associated with systemic dysregulation of immune function leading to a
heightened risk of infection and cardiovascular disease. In patients with AAV, CD4 + CD28null expansions are driven
by CMV and are associated with an increased risk of infection and mortality.
The aim of this study is to explore in detail the ways in which CMV modulates the immune system and to
determine whether treatment with valaciclovir blocks subclinical CMV reactivation in CMV seropositive AAV patients
and ameliorates the CMV-induced adverse effects on the immune system.
Methods/design: CANVAS is a single-centre prospective open-label randomised controlled proof-of-concept trial of
50 adult CMV seropositive patients with stable AAV. Participants will be randomly allocated to receive valaciclovir
orally (2 g QDS or reduced according to renal function) or no additional treatment for 6 months with an additional
6-month follow-up period. The primary outcome is the proportion of patients with CMV reactivation, as assessed by
measurable viral load on quantitative blood and urine CMV polymerase chain reaction. The secondary outcomes are
safety, change in the proportion of CD4+ CMV-specific T-cell population (defined as CD4 + CD28null cells) and
change in soluble markers of inflammation from baseline to 6 months. Further tertiary and exploratory outcomes
include persistence of the effect of valaciclovir on the proportion of CD4 + CD28null cells at 6 months post
completion of treatment, change in the immune phenotype of CD4+ T cells and change in blood pressure and
arterial stiffness parameters from baseline to 6 months.
Discussion: The results of this study will enable larger studies to be conducted to determine whether by
controlling subclinical CMV reactivation, we can improve clinical endpoints such as infection and cardiovascular
disease. The potential impact of this study is not limited to AAV, as CD4 + CD28null cells have been linked to
adverse outcomes in other inflammatory conditions and in the context of an ageing immune system.
Trial registration: ClinicalTrials.gov Identifier NCT01633476 (registered 29 June 2012).
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Background
The anti-neutrophil cytoplasmic antibody (ANCA) asso-
ciated vasculitides (AAV) are a group of rare systemic
autoimmune inflammatory chronic disorders that in-
clude granulomatosis with polyangiitis (Wegener’s gran-
ulomatosis) [1], microscopic polyangiitis, renal limited
vasculitis and eosinophilic granulomatosis with polyangii-
tis (Churg–Strauss syndrome) [2]. AAV are characterised
by necrotising inflammation affecting small to medium-
sized blood vessels leading to end organ damage com-
monly affecting the kidneys, lungs and upper airways.
They range in severity from localised disease affecting the
upper airways to life-threatening involvement giving rise
to multi-organ failure [3].
Over the last few decades, survival has greatly im-
proved from 20 % at 2 years to 78 % at 5 years following
diagnosis [4, 5]. However, survival remains below that of
the healthy population with infection, cardiovascular dis-
ease (CVD) and malignancy being the most common
causes of death.
Recently the role of T cells in AAV pathophysiology
and exacerbation of tissue damage has gained attention.
An increased percentage of CD4 T cells that have lost
expression of the co-stimulatory molecule CD28 (CD4 +
CD28null cells) have been reported in AAV [6]. Loss of
CD28 implies repeated antigen exposure and, in a previ-
ous study, we demonstrated that this phenotype in AAV
is driven by latent Cytomegalovirus (CMV) infection [7].
An expanded CD4 + CD28null cell population in this
study was associated with an increased risk of infection
and increased mortality in patients with AAV. In renal
transplant recipients, the presence of CD4 + CD28null
cell expansions is associated with a reduced response to
antigenic challenge [8] and in elderly donors this pattern
is also associated with frailty, reduced response to the
influenza vaccine and increased mortality [9, 10]. In
addition, CMV has been linked to a declining immune
system associated with advancing age, a concept termed
‘immunosenescence’ [11].
Furthermore, latent CMV infection has recently been
linked to increased arterial stiffness, a marker of CVD
risk, in patients with chronic kidney disease (CKD) [12].
CD4 + CD28null cell expansions in turn have been asso-
ciated with an increased risk of CVD in patients with
CKD as well as rheumatoid arthritis [13, 14]. Finally, in
vitro experiments have demonstrated that CD4+ CMV-
specific cells are able to target and damage the endothe-
lium via expression of the chemokine receptors CX3C-
chemokine-receptor-1 (CX3CR1) and CXCR3 that bind
their respective ligands fractalkine and interferon
gamma-induced protein 10 (IP-10), which are expressed
on the surface of activated endothelial cells [15]. As
such, considerable evidence suggests that CMV-specific
CD4 + CD28null cell expansions are associated with
systemic impairment and dysregulation of immune func-
tion leading to a heightened risk of infection and CVD,
two of the leading causes of morbidity and mortality in
AAV patients.
CMV reactivation is believed to occur in a relatively
frequent basis in vivo [16–18] and is thought to result in
gradual accumulation of CD4 + CD28null CMV-specific
effector T cells and a reduction in CD4+ naive T cells, a
phenomenon known as ‘memory inflation’ [19]. The
cytokine production of CMV-specific cells may also be
modulated over time correlating to loss of function. In a
study of elderly CMV seropositive patients, up to 50 %
of CMV-specific CD4+ T cells were unable to produce
interleukin-2 (IL-2) and were capable of only interferon
gamma (IFN-γ) production [20]. Associated with cyto-
kine modulation is an increase in the expression of in-
hibitory receptors, cytotoxic T-lymphocyte associated
protein 4 (CTLA-4), programmed cell death protein 1
(PD-1) and T-cell immunoglobulin and mucin domain
containing 3 (TIM-3) leading to attenuation of virus-
specific T-cell function [21]. On the other hand, several
studies have described CD4 + CD28null cells as a pro-
inflammatory cytotoxic subset capable of producing sig-
nificant amounts of IFN-γ, granzyme B and perforin,
which are implicated in endothelial damage and an in-
creased risk of CVD as alluded to earlier [22].
Prophylactic treatment with the anti-viral agent valaci-
clovir can suppress CMV replication in renal transplant
recipients [23] and treatment of viraemia reduces PD-1
expression and increases IL-2 production [24]. We hy-
pothesise that repeated episodes of sub-clinical CMV
replication in AAV patients drive the expansion and pos-
sible functional impairment of CD4 + CD28null CMV-
specific cells with a resultant increased susceptibility to
infection. We further hypothesise that inhibition of viral
replication with valaciclovir will ameliorate the expan-
sion of CD4 + CD28null cells and possibly increase the
functional capacity of the immune system in patients
with AAV.
We report here the study protocol for a randomised
controlled open-label proof-of-concept clinical trial
that aims to explore the ways in which CMV modu-
lates the immune system in patients with AAV and
investigate whether treatment with valaciclovir can
ameliorate this CMV-induced adverse modulation of
the immune system.
Methods/design
This is a single-centre open-label randomised controlled
trial of oral valaciclovir treatment (2 g four times a day;
reduced appropriately depending on renal function) for
6 months versus no additional treatment, in CMV sero-
positive patients with stable AAV, followed by a 6-month
follow-up period. No placebo will be used.
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The primary outcome is the proportion of patients
with CMV reactivation, as assessed by measurable viral
load on quantitative blood and urine CMV polymerase
chain reaction (PCR). The secondary outcomes are
safety, as defined by adverse events sufficient to stop
treatment with valaciclovir, change in the proportion
of the CD4+ CMV-specific T-cell population (defined
as CD4 + CD28null cells) and change in soluble
markers of inflammation from baseline to 6 months
(Table 1). Further tertiary and exploratory outcomes
include persistence of the effect of valaciclovir on the
proportion of CD4 + CD28null cells at 6 months post
completion of treatment, change in the immune
phenotype of CD4+ T cells and change in blood pres-
sure and arterial stiffness parameters from baseline to
6 months (Table 1).
Clinical trial authorisation has been obtained from the
Medicines and Healthcare Products Regulatory Agency
(MHRA) (EudraCT number 2012-001970-28). The trial
sponsor is the University of Birmingham and the
study will be run through the National Institute for
Health Research (NIHR) and Wellcome Trust (WT)
Clinical Research Facility (CRF) at the University
Hospital Birmingham (UHB) National Health Service
(NHS) Foundation Trust, which also hosts the UHB
Vasculitis Clinic. The trial is funded by WT and
Vasculitis UK. The trial will be coordinated by the
trial management group (TMG) in conjunction with
the NIHR/WT CRF according to the current guide-
lines for Good Clinical Practice (GCP) and ensuring
protection of patients’ rights as detailed in the Dec-
laration of Helsinki. All laboratory assays will be car-
ried out in laboratories that fulfil the principles of
Good Laboratory Practice and assays informing the
primary and secondary outcomes will be fully vali-
dated prior to study commencement. The protocol
was designed based on the SPIRIT guidelines (see
SPIRIT checklist; Additional file 1).
Table 1 Study endpoints
Description Specific measurement variable
Primary outcome
Proportion of patients with CMV reactivation Quantification of viral DNA copies in blood and urine by
quantitative polymerase chain reaction (qPCR)
Secondary outcomes
Safety Number of adverse events and incidence of events by
system organ class
Adverse events sufficient to stop treatment with study drug
Change in the proportion of CD4 + CD28null cells
from baseline to 6 months
Proportion of CD3 + CD4 + CD28- T cells in peripheral blood
Change in the concentration of soluble markers of
inflammation from baseline to 6 months
Concentration of IL-2, tumour necrosis factor alpha (TNF-α),
IFN-γ, IL-6, IL-10, IL-17 and highly sensitive C-reactive protein
(CRP) in peripheral blood
Tertiary outcome
Persistence of valaciclovir effect on the proportion
of CD4 + CD28null cells from 6 months to 12 months
Proportion of CD3 + CD4 + CD28- T cells in peripheral blood
Exploratory outcomes
Change in immune phenotype of CD4+ T cells from
baseline to 6 months
Proportion of CD4 + CD28null cells secreting IFN-γ, IL-2, TNF-α,
IL-5 and IL-10 in response to CMV lysate stimulation
Proportion of CD4 + CD28null cells expressing the inhibitory
receptors PD-1, TIM-3, CTLA-4 and lymphocyte activation
gene 3 (LAG-3)
Proportion of CD4 + CD28null cells expressing the transcription
factors T box expressed in T cells (T-bet) and positive regulatory (PR)
domain zinc finger protein 1 (BLIMP-1)
Proportion of CD4 + CD28null cells expressing the chemokine
receptors CX3CR1, CXCR3, C-C chemokine receptor type 5 (CCR5),
CD49d and CD11b
Proportion of CD4+ naive, central memory, effector memory
and terminally differentiated effector memory populations
Change in soluble markers of endothelial damage
from baseline to 6 months
Concentration of fractalkine, IP-10, regulated on activation, normal T cell
expressed and secreted (RANTES), P-selectin, E-selectin, monocyte
chemoattractant protein-1 (MCP-1), soluble vascular cell adhesion molecule
1 (sVCAM-1) and soluble intracellular cell adhesion molecule 1 (sICAM-1) in
peripheral blood
Change in markers of arterial stiffness from baseline
to 6 months
Measures of arterial stiffness: cfPWV, peripheral pulse pressure
and central pulse pressure
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Participants
In total, 50 CMV seropositive patients with AAV in stable
remission for 6 months or longer and on a maximum of
two immunosuppressant agents will be recruited from the
Vasculitis Clinic at UHB NHS Foundation Trust. Recruit-
ment will take place over 2 years. Our tertiary referral vas-
culitis clinic has more than 200 patients under long-term
follow-up. Approximately 90 % of patients are in remis-
sion at any one time and 70 % are seropositive for CMV.
CMV status is checked routinely at the patient’s first at-
tendance in the clinic. We anticipate that 125 of our pa-
tients attending the clinic will be eligible for this study.
Recruitment of 40 % would achieve the target of 50
patients. This is a conservative rate given our previous
experience. Patients will be approached at routine clinic
visits. Patients may also be contacted via post by sending
them a copy of the patient information sheet (see
Additional file 2). Patients will be allowed a minimum of
24 hours to reflect on the content of the patient informa-
tion sheet before written informed consent is obtained by
completion and signing of the study-specific informed
consent form (see Additional file 3).
A full list of study inclusion and exclusion criteria is
given in Table 2. Subjects will be withdrawn from the
trial if they choose not to continue or the investigators
feel that continued participation in the trial is inappro-
priate. Subjects who withdraw from the intervention will
be asked if they are prepared to continue to attend
follow-up clinics. The study’s primary and main second-
ary outcomes are based on objective laboratory assays,
therefore, minimising the risk of performance bias in
this open-label design. Furthermore, treatment and med-
ical management other than valaciclovir will be identical
between the treated and control patients.
Schedule of assessments
Patients will attend for a total of 14 visits over a period
of just over 12 months (Fig. 1). Evaluation of CMV re-
activation by deoxyribonucleic acid (DNA) PCR of blood
and urine will be done monthly. Evaluation of the toler-
ability of the drug and adverse events will occur
monthly. Immune assessments as detailed below and in
Table 1 will be performed at entry, 6 months and 12
months (Fig. 1).
After providing written informed consent, the patients
will undergo an initial pre-baseline visit. During this
visit, a 5-ml blood sample will be drawn, which will be
used to determine the percentage of CD4 + CD28null
cells. This value will be utilised in the randomisation of
patients as explained below.
At the baseline, 6-month and 12-month visits, a total
of 50 ml of blood will be drawn in addition to a 50-ml
sample of urine. The samples will be used to determine
CMV viral copies by DNA PCR in blood and urine
(primary outcome), the proportion of CD4 + CD28null
cells in peripheral blood by flow cytometry (secondary
outcome), the concentration of soluble markers of inflam-
mation (Table 1) in peripheral blood (secondary outcome)
and immune assessments and T-cell phenotyping as de-
tailed in the exploratory outcomes (Table 1). Excess sam-
ple will be stored appropriately. Blood pressure and
arterial stiffness measurements will also be carried out at
the baseline, 6-month and 12-month visits as detailed
below.
During the remainder of the monthly visits, a 10-ml
blood sample will be drawn in addition to a 50-ml sam-
ple of urine, which will be used to determine CMV viral
copies by DNA PCR in blood and urine (primary out-
come). Excess sample will again be stored appropriately.
In addition, safety blood tests as defined below will be
performed monthly for the duration of treatment for
those patients randomised to receive the drug.
Appointments will be scheduled on monthly with an
allowance of 10 days either side of the estimated due
Table 2 Study inclusion and exclusion criteria
Inclusion criteria
Documented diagnosis of granulomatosis with
polyangiitis (Wegener’s), microscopic polyangiitis
or renal limited vasculitis according to Chapel Hill
Consensus Conference Criteria
In stable remission (no documented clinical
disease activity) for at least 6 months prior
to study entry
On maintenance immunosuppression with
prednisolone, mycophenolate mofetil or
azathioprine alone or in combination
(maximum two agents)
Documented past evidence (any time point)
of CMV infection (CMV-specific immunoglobulin
G detected in peripheral blood)
Documentation that female patients of child-
bearing potential are not pregnant and are
using an appropriate form of contraception
Written informed consent for study participation
Exclusion criteria
Stage 5 CKD (estimated glomerular filtration rate (eGFR)
<15 ml minute-1 1.73 m-2);
tests performed within 6 months of pre-baseline
visit can be used for this assessment
Other significant chronic infection (HIV, hepatitis B,
hepatitis C or tuberculosis)
B-cell depleting therapy within 12 months or T-cell
depleting therapy within 6 months
Treatment with anti-CMV therapies in the last
month
Underlying medical conditions, which in the
opinion of the investigator place the patient
at unacceptably high risk for participating in
the study
Inability to participate fully or appropriately in
the study
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date of the monthly appointment to allow for patient
convenience and flexibility. The overall treatment period
(or control period) of 6 months will also be subject to
the same 10-day rule to avoid excessive movement of
the length of treatment.
Study assessments
Enumeration of CMV DNA copies for the determination
of the primary outcome (CMV reactivation) will be car-
ried out by PCR of plasma and urine. This assessment
will be performed by the UHB Virology Laboratory
using an existing validated assay utilised for clinical
samples.
Whole blood will be stained with fluorochrome conju-
gated monoclonal antibodies to CD3, CD4 and CD28
and analysed via flow cytometry (LSR II Flow Cytometer,
DIVA Software; BD) to determine the proportion of
CD4 + CD28null cells in peripheral blood. Plasma will be
assessed via Luminex technology to determine the sol-
uble markers of inflammation (Table 1). These assays
will be validated for precision and reproducibility prior
to commencement of the trial (see also the laboratory
manual; Additional file 4).
Determination of blood pressure and arterial stiffness
will be conducted using the Vicorder system (Skidmore,
Bristol, UK) [25, 26]. Carotid to femoral pulse wave vel-
ocity (cfPWV) will be used to estimate arterial stiffness.
The Vicorder system provides a non-invasive non-
operator dependent method of obtaining cfPWV using a
volume displacement method. Patients will be allowed to
rest in a supine 30° head tilt position for 5 minutes prior
to inflating a 100-mm-wide blood pressure cuff on the
non-dominant arm to determine peripheral blood pres-
sure. A 30-mm-wide partial cuff will be placed on the
neck at the level of the carotid artery and a 100-mm-
wide blood pressure cuff will be placed around the prox-
imal thigh. The distance between the mid-clavicular
point and the mid-point of the thigh cuff will be mea-
sured and entered in the Vicorder instrument as the aor-
tic path length. The neck and thigh cuffs will then be
inflated to 60 mm Hg and the Vicorder instrument will
utilise the resultant oscillometric signal to extract the
pulse waveforms and pulse transit time to calculate
cfPWV. The mean value of three consistent recordings
will be used for subsequent analysis. Inconsistent values
will be re-analysed by a senior independent examiner
not involved in taking the measurements to determine
the validity of each measurement.
Randomisation
Randomisation will be undertaken using the independ-
ent telephone-based randomisation system of the Pri-
mary Care Clinical Research and Trials Unit at the
University of Birmingham (which is fully accredited by
Fig. 1 SPIRIT figure showing study’s schedule of enrolment, intervention and assessment. M0 baseline visit, M1 to M12 month 1 to month 12,
qPCR quantitative polymerase chain reaction. *Safety blood tests will be performed only on treatment group
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the NIHR as a trials unit). We will employ block ran-
domisation by CD4 + CD28null cell percentage stratifica-
tion (cut-off 40 %). The randomisation will use mixed
blocks of random size (two, four or six) not known to
the research team, therefore, minimising any risk of se-
lection bias.
Treatment
Patients randomised to the treatment arm will receive 2
g of valaciclovir orally four times a day. The dose will be
reduced appropriately depending on renal function
(Table 3). The study is open label and valaciclovir will be
used off the shelf with no modifications to the packaging
or labelling of the product. Patients will be asked to re-
turn unused tablets at each monthly visit to monitor
compliance with medication. Patients randomised to the
control arm will receive no additional treatment. Safety
blood tests will be conducted monthly for the duration
of treatment for the patients randomised to valaciclovir
and these will comprise a full blood count, urea and
electrolyte levels, and liver function tests. In the event of
toxicity of grade 2 or less (scored using the National
Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events version 4.0), the adverse event will be
discussed with one of the investigators to determine
whether drug administration should be temporarily
withdrawn or the dose reduced. In the event of toxicity
of grade 3 or more, the adverse event will be discussed
with the principal investigator. In such a case, the ex-
pectation will be to withdraw drug administration for 1
week unless the adverse event is judged by the principal
investigator to be unrelated to the study drug. Reintro-
duction of the drug will be based on a clinical review.
The collection and reporting of data on adverse events
and serious adverse events will be in accordance with
EU directive 2001/20/EC and UK legislation.
Sample size calculation and planned statistical analyses
In an immunocompetent elderly population, CMV re-
activation occurred in 90 % at 6 months [18]. It is ex-
pected that CMV reactivation will be at least that in our
immunosuppressed population. Information for dosing
regimens using antiviral prophylaxis in renal transplant
recipients has demonstrated over 90 % suppression of
CMV reactivation. Our sample size assumes 90 % re-
activation in the control limb and a conservative esti-
mate of 50 % reactivation in the treated group. The
estimated sample size is 50 patients, 25 patients in
each arm, based on 80 % power at a significance level
of p < 0.05 (two-tailed test).
All analyses will be performed using the intention-to-
treat principle. Baseline covariates will be compared
between the two arms to observe the balance and the
success of randomisation. The primary analysis will test
the hypothesis that there is no difference in the propor-
tion of patients with CMV reactivation between those
receiving antiviral prophylaxis compared with those
receiving usual treatment. For the secondary out-
comes, comparisons will be made between groups
using absolute measures of immune function and
change between data at entry and end of treatment
within groups. Missing data will be dealt with by
simple imputation if missing randomly. Where data
are missing systematically, appropriate statistical
models will be applied to avoid attrition bias. A full
statistical analysis plan will be written and approved
prior to data analysis.
A safety analysis will be performed on all treated pa-
tients. The number of events and incidence of adverse
events by system organ class will be summarised and the
relationship to the treatment noted.
The final report will follow the CONSORT 2010
guidelines and will be published in a peer-reviewed
journal. Authorship will be based on the International
Committee of Medical Journal Editors guidelines.
Results will be communicated to study participants and
patient groups through presentations at patient and
carer group meetings.
Trial management and monitoring
The trial will be coordinated by the TMG (principal in-
vestigator, co-investigators and statistical advisor) in
conjunction with the NIHR/WT CRF. A trial steering
committee (TSC) that will include the TMG as well as
two independent consultant nephrologists not involved
in the study or regular review of patients recruited in
the trial will provide the overall supervision of the trial.
The TSC will oversee trial progress, protocol compli-
ance, patient safety and review of updated information.
Part of the role of the TSC will be to review safety data
after the first ten patients have completed treatment. As
this is a small proof-of-concept study with a short follow-
up, no data monitoring committee will be formed, as
agreed with the sponsor. Any protocol amendments will
be submitted to the sponsor and relevant regulatory bod-
ies for approval prior to implementation and trial partici-
pants will be informed of any protocol modifications. The
University of Birmingham will conduct regular audit visits
Table 3 Dose modification of valaciclovir according to
creatinine clearance
Creatinine clearance (CrCl ml/min)a Valaciclovir dose
>75 2 g four times a day
51–75 1.5 g four times a day
26–50 1.5 g three times a day
10–25 1.5 g two times a day
aTests performed within 6 months of the pre-baseline visit can be used for
this assessment
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in its capacity as the trial sponsor to ensure compliance
with the protocol and adherence to GCP and regulations.
The integrity of data entry will be ensured using a
trial-specific Data Input Quality Control standard oper-
ating procedure (Trial Master File, University of Bir-
mingham). Samples will be anonymised and all analyses
will be undertaken on anonymised datasets with study
identifiers replacing personal data. All personal details
will be kept on NHS secure password-protected servers
within UHB NHS Trust. Anonymised data will be trans-
ferred to password-protected servers in the University of
Birmingham for analysis. No data will be stored on com-
puter hard drives. All staff have confidentiality clauses in
their honorary and substantive contracts.
Discussion
Infection and CVD represent two of the leading causes
of death in patients with AAV. Expansions of CD4 +
CD28null T cells in AAV that are driven by latent CMV
infection have previously been shown to be associated
with an increased risk of infection and mortality, whilst
in other inflammatory disorders, such as CKD and
rheumatoid arthritis, CD4 + CD28null cell expansions
are linked to an increased risk of CVD. This randomised
controlled proof-of-concept clinical trial will investigate
in more detail the ways via which CMV adversely modu-
lates the immune system in AAV and test the hypothesis
that via blocking subclinical CMV reactivation with vala-
ciclovir, it is possible to ameliorate such CMV-driven
adverse modulation and improve the functional capacity
of the immune system in AAV.
The results of this study will enable larger studies to be
conducted to determine whether by controlling subclinical
CMV reactivation in AAV, we can improve clinical end-
points, such as risk of infection, incidence of cardiovascu-
lar events and mortality. The potential impact of this
study is not limited to AAV, as CD4 + CD28null cells have
been linked to adverse outcomes in other inflammatory
conditions and in the context of an ageing immune
system.
Trial status
As at the time of submission, the CANVAS study is in
the process of patient recruitment.
Protocol amendments
Version 1.1 was approved on 21 August 2012.
Version 1.4 was approved on 19 December 2012.
Version 1.5 was approved on 29 July 2013.
Version 1.6 was approved on 23 December 2013.
Version 1.7 was approved on 2 June 2014.
Version 2.0 was approved on 19 November 2014.
Version 2.1 was approved on 5 March 2015.
Sponsor
The CANVAS study is sponsored by the University of Bir-
mingham (Dr Sean Jennings, Research Governance and
Ethics Manager, Research Support Group, University of
Birmingham, Edgbaston, Birmingham, B15 2TT, UK). The
University of Birmingham holds public liability (negligent
harm) and clinical trial (negligent harm) insurance pol-
icies, which apply to this trial. The sponsor has been in-
volved in protocol design as well as the development of
the case report form and assay validation plans.
Dissemination policy
It is anticipated that the findings of this study will be
published in peer-reviewed journals and that the results
will be disseminated to all study participants who wish
to be informed.
Additional files
Additional file 1: Complete SPIRIT checklist. (DOC 122 kb)
Additional file 2: CANVAS Version 1.4 of the participant information
sheet. (PDF 293 kb)
Additional file 3: CANVAS – Consent Version 1.4 of the consent form.
(PDF 139 kb)
Additional file 4: CANVAS – Lab Manual Version 3.0 of the trial
laboratory manual. (DOCX 181 kb)
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